risedronic acid has been researched along with Cachexia in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human breast cancer frequently metastasizes to the skeleton to cause osteolysis and subsequent pain, pathological fracture, and hypercalcemia." | 1.29 | Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. ( Boyce, BF; Boyce, R; Chapman, M; Mundy, GR; Sasaki, A; Story, B; Wright, KR; Yoneda, T, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sasaki, A | 1 |
| Boyce, BF | 1 |
| Story, B | 1 |
| Wright, KR | 1 |
| Chapman, M | 1 |
| Boyce, R | 1 |
| Mundy, GR | 1 |
| Yoneda, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for risedronic acid and Cachexia
| Article | Year |
|---|---|
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cachexia; Diphosphonates; Etidronic Acid | 1995 |